SCHEMBL101371

SCHEMBL101371

C/C=C/CC(C)C(O)C1C(=O)NC(C(C)C)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 14/20 0.89
PPIA P62937 5/20 0.89
ABCC1 P33527 2/20 0.89
ABCC2 Q92887 2/20 0.89
FKBP1B P68106 2/20 0.89
PPP3CA Q08209 2/20 0.89
MEN1 O00255 1/20 0.89
NPC1 O15118 1/20 0.89
ABCC3 O15438 1/20 0.89
GMNN O75496 1/20 0.89
USP2 O75604 1/20 0.89
SLCO2B1 O94956 1/20 0.89
ABCB11 O95342 1/20 0.89
LMNA P02545 1/20 0.89
POLB P06746 1/20 0.89
CYP3A4 P08684 1/20 0.89
MAPT P10636 1/20 0.89
RARB P10826 1/20 0.89
CYP2C9 P11712 1/20 0.89
CYP3A5 P20815 1/20 0.89

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1708943 1.00 ABCB1 (0.89) ABCB1PPIAABCC1ABCC2FKBP1B
SCHEMBL18163232 1.00 ABCB1 (0.89) ABCB1PPIAABCC1ABCC2FKBP1B
SCHEMBL16596082 0.98 ABCB1 (0.89) ABCB1PPIAABCC1ABCC2FKBP1B
SCHEMBL22033395 0.98 ABCB1 (0.89) ABCB1PPIAABCC1ABCC2FKBP1B
SCHEMBL102191 0.98 ABCB1 (0.89) ABCB1PPIAABCC1ABCC2FKBP1B
SCHEMBL19646863 0.98 ABCB1 (0.89) ABCB1PPIAABCC1ABCC2FKBP1B
SCHEMBL439348 0.98 ABCB1 (0.89) ABCB1PPIAABCC1ABCC2FKBP1B
SCHEMBL22032784 0.98 ABCB1 (0.89) ABCB1PPIAABCC1ABCC2FKBP1B
SCHEMBL23110210 0.94 ABCB1 (1.00) ABCB1PPIAABCC1ABCC2FKBP1B
Cyclosporine SCHEMBL24239036 0.94 ABCB1 (1.00) ABCB1PPIAABCC1ABCC2FKBP1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 800 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339520-A1 COMPOSITIONS AND METHODS FOR USE IN KRAS-TARGETED THERAPIES FOR THE TREATMENT OF CANCER RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-11-06 US claimed
US-12201669-B2 Small molecule suppressors of APOE gene expression and cerebral vascular amyloid pathology MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-01-21 US claimed
CN-115266996-B Analysis method and application of related substances in cyclosporine A preparation 兆科(广州)眼科药物有限公司 2024-04-30 CN claimed
CN-115266996-A Analysis method and application of related substances in cyclosporin A preparation 兆科(广州)眼科药物有限公司 2022-11-01 CN claimed
US-20220288157-A1 SMALL MOLECULE SUPPRESSORS OF APOE GENE EXPRESSION AND CEREBRAL VASCULAR AMYLOID PATHOLOGY MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2022-09-15 US claimed
WO-2022192716-A1 SMALL MOLECULE SUPPRESSORS OF APOE GENE EXPRESSION AND CEREBRAL VASCULAR AMYLOID PATHOLOGY MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2022-09-15 WO claimed
CN-112358532-A Closed cycle high-speed countercurrent chromatography for preparing cyclosporine D 浙江省林业科学研究院 2021-02-12 CN claimed
EP-2931299-B1 NOVEL PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF PERIODONTAL DISEASE PERIOC LTD (GB) 2019-02-06 EP claimed
CN-108715606-A The method of the cyclic annular ten monoamino-acid peptides of production 诺华股份有限公司 2018-10-30 CN claimed
US-10065992-B2 Cyclosporin analogs ALLERGAN, INC. (US) 2018-09-04 US claimed
WO-1997018828-A1 INHIBITORS OF CYCLOPHILIN ROTAMASE ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1997-05-29 WO claimed
WO-1997015269-A2 METHOD, COMPOSITIONS AND KITS FOR INCREASING THE ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS BAKER NORTON PHARMACEUTICALS, INC. (US) 1997-05-01 WO claimed
EP-0760237-A1 Oil-in-water microemulsions CIPLA LIMITED (IN) 1997-03-05 EP claimed
US-5051402-A Fungicides, immunosuppressants and antiphlogistic agents SANKYO COMPANY, LIMITED (JP) 1991-09-24 US claimed
WO-1990000389-A1 FREEZE-DRIED LIPOSOME COMPOSITIONS CONTAINING CYCLOSPORIN REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1990-01-25 WO claimed
US-4727035-A RADIOACTIVE OR FLUORESCENT LABELS SANDOZ LTD. (CH) 1988-02-23 US claimed
US-4388307-A CYCLOSPORIN WITH CARRIER OF VEGETABLE OIL, POLYALKYLENE GLYCOL TRANSESTERIFIED VEGETABLE OIL AND ETHANOL SANDOZ LTD. (CH) 1983-06-14 US claimed
US-4289851-A Process for producing cyclosporin derivatives SANDOZ LTD. (CH) 1981-09-15 US claimed
US-4288431-A CULTURING TOLYPLOCLADIUM, CATALYTIC HYDROGENATION, REARRANGEMENT; ANTIINFLAMMATORY, IMMUNOLOGY SANDOZ LTD. (CH) 1981-09-08 US claimed
US-4220641-A CYCLOSPORIN D, DIHYDROCYCLOSPORIN D AND ISOCYCLOSPORIN D, ANTIARTHRITIC, ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE SANDOZ LTD. (CH) 1980-09-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12201669-B2 Small molecule suppressors of APOE gene expression and cerebral vascular amyloid pathology APOL1, LDLR, APP ABCB1 113/4885PPIA 1861/4885ABCC1 214/4885
US-10065992-B2 Cyclosporin analogs CHP1, TSLP, PPP3R1 ABCB1 777/4885PPIA 202/4885ABCC1 693/4885
US-20220288157-A1 SMALL MOLECULE SUPPRESSORS OF APOE GENE EXPRESSION AND CEREBRAL VASCULAR AMYLOID PATHOLOGY APOL1, LDLR, APP ABCB1 113/4885PPIA 1861/4885ABCC1 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.